WuXi AppTec Reports Impressive First Half Results for 2026 and Increases Full-Year Projections

In a recent announcement, WuXi AppTec, a premier global provider of pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization) services, revealed its financial performance for the first half of 2026, showcasing outstanding results and an optimistic outlook for the rest of the year.

The company reported that its total revenue reached an impressive RMB 28.90 billion, marking a 38.9% increase compared to the same period last year. Additionally, revenues from Continuing Operations saw a remarkable growth of 48.0% year-over-year. These figures highlight WuXi AppTec's steadfast position in the market, attributable largely to the successes of its clientele and its distinctive, integrated CRDMO model.

Financial Highlights

Throughout the reporting period, various key financial metrics demonstrated capacity for robust growth. The adjusted non-IFRS gross profit margin surged by 9.4 percentage points year-on-year, achieving 53.9%. Meanwhile, the adjusted non-IFRS net profit rose significantly by 83.2%, which translates to RMB 11.57 billion, resulting in an adjusted net profit margin increase of 9.7 points to 40.0%. Furthermore, WuXi’s adjusted diluted earnings per share climbed 78.2% year-on-year to RMB 3.92.

The backlog for Continuing Operations also saw a notable increase, rising by 25.2% year-on-year to reach RMB 66.43 billion as of June 30, 2026. In terms of cash flow, adjusted operating cash flow increased by 41.3% to RMB 9.98 billion, illustrating a solid financial foundation.

Management Remarks

Dr. Ge Li, Chairman and CEO, expressed gratitude for the firm’s growth, linking it directly to the triumphant performance of its customers. He stated, “Our achievements are rooted in the exceptional performance of our customers. Driven by their success, our unique CRDMO model, and our global team’s commitment to excellence, we have delivered strong growth across revenue, profit, and cash flow.” He noted the firm’s backlog for Continuing Operations which now stands at an impressive RMB 66.4 billion, prompting the raised guidance for all metrics in 2026 and an acceleration in global capacity expansion.

Dr. Li also addressed a recent legal issue, informing stakeholders that WuXi was inaccurately included in a U.S. Department of Defense list, a designation the company strongly contests. Legal actions have been initiated to protect the interests of its employees, customers, and shareholders, with confidence in the outcome of the judicial review.